New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
May 29, 2014
07:06 EDTINSYInsys Therapeutics submits Type II DMF to FDA for CBD API
Insys Therapeutics announced it has submitted a Type II Drug Master File, or DMF, to the FDA for its cannabidiol, or CBD, active pharmaceutical ingredient, or API, and has been issued DMF# 28255. Insys recently announced plans to advance development of its pharmaceutical CBD program for the treatment of epilepsy in children and adults.
News For INSY From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
November 24, 2014
07:04 EDTINSYInsys Therapeutics receives FDA orphan drug designation to CBD candidate
Insys Therapeutics announced that the FDA has granted orphan drug designation, or ODD, to its pharmaceutical cannabidiol, or CBD, candidate for the treatment of pediatric schizophrenia. This marks the fifth ODD for the company's CBD program.
November 19, 2014
12:04 EDTINSYInsys Therapeutics cannabidiol receives FDA orphan designation
Subscribe for More Information
November 12, 2014
10:00 EDTINSYOn The Fly: Analyst Downgrade Summary
Subscribe for More Information
08:15 EDTINSYInsys Therapeutics downgraded at Oppenheimer
As noted earlier, Oppenheimer downgraded Insys to Perform from Outperform. The firm believes that the stock values Suybsys fairly at current levels, while the company's nearest-term pipeline opportunities will likely not materialize until 2016.
07:55 EDTINSYInsys Therapeutics downgraded to Perform from Outperform at Oppenheimer
Subscribe for More Information
November 11, 2014
06:52 EDTINSYInsys Therapeutics reports Q3 non-GAAP EPS 63c, consensus 29c
Subscribe for More Information
November 10, 2014
15:26 EDTINSYNotable companies reporting before tomorrow's open
Notable companies reporting before tomorrow's market open, with earnings DR Horton (DHI), consensus 48c; Sabre (SABR), consensus 26c; AECOM Technology (ACM), consensus 82c; CST Brands (CST), consensus 57c; Qiwi plc (QIWI), consensus 36c; INSYS Therapeutics (INSY), consensus 29c.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use